Healthcare Industry News: i-STAT
News Release - December 1, 2009
Wound Management Technologies' CellerateRx Receives further Press at VA Conference; Statistical Evidence MountsFORT WORTH, Texas, Dec. 1 (Healthcare Sales & Marketing Network) -- Wound Management Technologies, Inc. (OTC Bulletin Board: WNDM ) a rapidly growing provider of specialty medical products, announced today that further positive case study data on CellerateRx(R), the core product of the Wound Care Innovations, LLC operating subsidiary, was released at the recent 6(th) Annual High Risk Diabetic Foot Conference for VA Podiatrists and Healthcare Professional in Tempe, AZ.
One of the Wound Technology Symposium's sessions was "The Benefits of Collagen in Wound Healing: Method of Action and Selection of Collagen Containing Dressings" by Jane Fore, MD, FAPWCA, FACCWS, Medical Director, Tri-STATe Wound Care and Hyperbaric Center. Included in her presentation was Wound Care Innovations' advanced wound care product, CellerateRx(R). "I have been using CellerateRx in my wound care protocols for over 5 years and it is an essential part of my wound care treatments for success," summarized Dr. Fore. "I particularly like the versatility of the powder and gel which I can use without wasted product, and the biocompatibility of the type 1 bovine collagen in the activated form which is ready for use immediate use by the wound. This is a product that can be safely used in conjunction with other products because of compatibility and will enhance the activity of many other wound care treatments when combined with other regimens. "
"We were delighted to be a part of this exciting conference. Dr. Jane Fore is a leading authority in the wound care field, and we welcome her findings," states Cathy Bradshaw, President of Wound Care Innovations. "This was the largest meeting that they have held and included leading experts in a variety of disciplines from within as well as external to the VA. Diabetic wounds and the incidence of amputations is a serious issue in healthcare. This conference focused on the principles of amputation prevention both in the VA and Federal Service and the non-government sectors. Our product successfully addresses a five billion dollar worldwide market."
CellerateRx(R) is FDA cleared for acute and chronic wounds which include but are not limited to: diabetic ulcers, venous stasis ulcers, ulcers due to arterial insufficiency, pressure ulcers stages I-IV, surgical wounds, traumatic wounds, superficial wounds, and 1(st) and 2(nd) degree burns. It comes in two forms, a powder which is about 95% collagen, and a gel which is about 65% collagen, and contains no additives or synthetics. CellerateRx(R) is manufactured in the United States. "Several independently run evidence-based studies have certified our product's value, and the overwhelmingly positive data can now be accessed at www.woundmanagementtechnologies.com ," said Cathy Bradshaw, President of Wound Care Innovations, the division that markets CellerateRx.
"We realize we are not Johnson and Johnson when it comes to developing evidence based studies of our products or with 300 plus in house sales reps, but over the past year we have been meeting milestones to take WNDM to the next level. We have recently assembled a national sales force of over 40 independent reps selling in addition to our extensive international distribution channel," stated WNDM CEO Scott Haire. "The third quarter 2009 numbers show that our efforts are paying off; our next benchmark is to become profitable in 2010 and bring earnings to the bottom line as quickly as possible".
For Wound Management Technologies Shareholder Information please call 954-357-0614.
About Wound Management Technologies, Inc.
Wound Management Technologies, Inc. (OTC Bulletin Board: WNDM ), with its corporate headquarters in Fort Worth, Texas, and regional offices in Ft. Lauderdale, Florida is a rapidly growing provider of specialty medical products and advanced biotechnology solutions. The Company is following the lead of NASDAQ Biotech Stock INDEX leaders such as Celgene (CELG) http://www.celgene.com, Geron (GERN) http://www.geron.com, and Human Genome Sciences (HGSI) http://www.hgsi.com by working to leverage its existing technology and infrastructure to develop opportunities within the International Biotechnology and Genetic Engineering fields. WNDM also has an interest in Cancer Treatment. For more information on the Company please visit http://www.woundmanagementtechnologies.com or call our shareholder information department at 954-357-0614.
"Safe Harbor" Statement: Under The Private Securities Litigation Reform Act of 1995: The statements in the press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development are "forward-looking statements," within the meaning of the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company's operations, current and future performance and financial condition. These items involve risks and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks and uncertainties detailed in the Company's SEC filings. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.
Source: Wound Management Technologies
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.